Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type ...( Phase 3 data highlight sustained eff...),Health

Phase 3 data highlight sustained efficacy and benefits of early treatment

with liraglutide versus glimepiride

SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Data presented today at the 68th Scientific Sessions of the American Diabetes Association (ADA) demonstrated that once-daily liraglutide when taken alone produced statistically significant improvement in blood sugar (glucose) control in patients with type 2 diabetes, as compared to glimepiride, a widely used oral anti-diabetic drug (OAD).

To view the Multimedia News Release, go to:

http://www.prnewswire.com/mnr/novonordisk/33424/

In addition, liraglutide demonstrated the following benefits compared to glimepiride:

-- Statistically significant reduction in body weight

-- Statistically significant reduction in risk of hypoglycemia

-- Statistically significant reduction in systolic blood pressure

In this 12-month study, 62% of patients treated with liraglutide who had not been previously treated with diabetes medications achieved an average reduction in blood sugar that brought them below the ADA target for HbA1c of 7%.

"This study showed that when used as initial drug treatment for type 2 diabetes, once-daily liraglutide not only statistically significantly reduced blood glucose, weight, and systolic blood pressure, but sustained blood glucose reductions for the duration of the study in patients who had never taken diabetes medications before," said study investigator Robert E. Ratner, MD, Vice President for Scientific Affairs at the MedStar Research Institute in Washington, DC. "The sustained reduction in blood glucose suggests that liraglutide may be beneficial when used earlier in the course of diabetes."

About the Study

The data presented today are from the LEAD(TM) 3 study, one of the five studies which make up the Phase 3 pro
'/>"/>